🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Realgar-Indigo Naturalis Formulation Combined with Anlotinib

    The First People's Hospital of Lianyungang

    Platinum-resistant Ovarian Cancer (PROC)

    approved small molecule active

    1 trial

  2. Rebamipide 2% ophthalmic solution

    Samsung Bioepis NL B.V.

    Dry Eye Disease (DED)

    approved small molecule active

    1 trial

  3. Recaticimab

    The First People's Hospital of Lianyungang

    STEMI - ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  4. Recombinant FSH (follitropin alpha)

    United Therapeutics Europe Ltd

    Ovulation Induction

    approved small molecule completed

    1 trial

  5. Recombinant Human Adenovirus Type 5 injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    approved small molecule active

    1 trial

  6. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    ST-segment Elevation Myocardial Infarction (STEMI)

    approved small molecule completed

    1 trial

  7. Recombinant Staphylokinase

    The First People's Hospital of Lianyungang

    Acute Myocardial Infarction

    approved small molecule completed

    1 trial

  8. Recombinant staphylokinase

    The First People's Hospital of Lianyungang

    ST Elevation Myocardial Infarction

    approved small molecule active

    1 trial

  9. Regadenoson

    Aspire Biopharma Holdings

    Coronary Artery Disease

    approved small molecule completed

    1 trial

  10. Regimen：BIC+FTC+TAF

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV Infection

    approved small molecule active

    1 trial

  11. Regiocit solution pour hémofiltration

    Pari Pharma GmbH

    Adult patients hospitalized in intensive care with an indication of EER with ARC during the stay.

    approved small molecule active

    1 trial

  12. Regional Anesthesia

    BRIGHT MINDS BIOSCIENCES INC.

    Inguinal Hernia

    approved small molecule completed

    1 trial

  13. Reinforcement Based Treatment

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    approved other completed

    1 trial

  14. Rematazolam Besylate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Emergence Agitation

    approved small molecule active

    1 trial

  15. Remimazolam Besylate for Injection

    The First People's Hospital of Lianyungang

    Thoracic Surgery

    approved small molecule active

    1 trial

  16. Remodulin

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    approved small molecule completed

    1 trial

  17. Remsima 100 mg powder for concentrate for solution for infusion

    Disc Medicine

    Crohn's Disease

    approved small molecule active

    1 trial

  18. Renin-angiotensin system blockers

    Hospital Authority, Hong Kong

    Diabetes

    approved small molecule active

    1 trial

  19. Repatha 140 mg solution for injection in pre-filled pen

    Pari Pharma GmbH

    acute myocardial infarction

    approved small molecule active

    1 trial

  20. Rescue Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Neovascular Polypoidal Choroidal Vasculopathy

    approved small molecule active

    1 trial

  21. Revefenacin

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease

    approved small molecule completed

    1 trial

  22. Rifaldin 300 mg cápsulas, Rimactán 300 mg cápsulas duras, Cemidón 300 B6, RIFAPENTINE

    The George Institute

    Latent tuberculosis infection in patients with end-stage kidney disease.

    approved small molecule active

    1 trial

  23. Rifaximin

    United Therapeutics Europe Ltd

    Clostridium Difficile Infection

    approved small molecule completed

    1 trial

  24. Rituximab

    The First People's Hospital of Lianyungang

    Hemophagocytic Lymphohistiocytosis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources